Company Filing History:
Years Active: 2007
Title: Yudong Hu: Innovator in Cancer Therapeutics
Introduction
Yudong Hu is a prominent inventor based in Baltimore, MD, known for his significant contributions to cancer research. He has developed innovative solutions aimed at improving the diagnosis and treatment of various cancers. His work focuses on monoclonal antibodies that target specific cancer cells, providing new avenues for therapy.
Latest Patents
Yudong Hu holds a patent for a monoclonal antibody known as 7H11, which is reactive with human cancer. This novel monoclonal antibody and its binding fragments are specifically designed to target human breast cancer, lung cancer, colon cancer, and other malignancies. Notably, the antibody does not bind to the cell surface of normal human tissues, ensuring tumor specificity. The patent also discloses the corresponding cancer-specific antigen with an apparent molecular weight of 150 kd, along with polynucleotides encoding the antigen and the CDR regions of the antibody. The methods outlined in the patent are applicable for the diagnosis, prognosis, and treatment of human breast cancer, making it a valuable asset in oncology.
Career Highlights
Yudong Hu is currently associated with A&G Pharmaceutical, Inc., where he continues to advance his research in cancer therapeutics. His work has the potential to revolutionize how cancers are diagnosed and treated, providing hope for improved patient outcomes.
Collaborations
Some of Yudong Hu's notable coworkers include Le Sun and Ginette Serrero, who contribute to the collaborative efforts in cancer research and development.
Conclusion
Yudong Hu's innovative work in developing monoclonal antibodies represents a significant advancement in cancer treatment. His contributions are paving the way for more effective diagnostic and therapeutic options for patients battling cancer.